ImmuPharma (LON:IMM) Trading 15% Higher – Should You Buy?

ImmuPharma plc (LON:IMM) shares shot up 15% on Thursday . The company traded as high as GBX 13.85 ($0.19) and last traded at GBX 13 ($0.18). 13,221,054 shares traded hands during mid-day trading, an increase of 53% from the average session volume of 8,639,387 shares. The stock had previously closed at GBX 11.30 ($0.15).

ImmuPharma Stock Performance

The company has a market cap of £67.15 million, a price-to-earnings ratio of -1,509.89 and a beta of 1.53. The stock’s fifty day moving average is GBX 5.71 and its two-hundred day moving average is GBX 3.70.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.